Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.56 (
insulin-degrading enzyme
)
737
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
There is a significantly higher risk for type II diabetes in HIV-1 carriers, albeit the molecular mechanism for this HIV-related pathology remains enigmatic. The 52 amino acid HIV-1 p6 Gag protein is synthesized as the C-terminal part of the Gag polyprotein Pr55. In this context, p6 promotes virus release by its two late (L-) domains, and facilitates the incorporation of the viral accessory protein Vpr. However, the function of p6 in its mature form, after proteolytic release from
Gag
, has not been investigated yet. We found that the mature p6 represents the first known viral substrate of the ubiquitously expressed cytosolic metalloendopeptidase
insulin-degrading enzyme
(
IDE
).
IDE
is sufficient and required for degradation of p6, and p6 is approximately 100-fold more efficiently degraded by
IDE
than its eponymous substrate insulin. This observation appears to be specific for HIV-1, as p6 proteins from HIV-2 and simian immunodeficiency virus, as well as the 51 amino acid p9 from equine infectious anaemia virus were insensitive to
IDE
degradation. The amount of virus-associated p6, as well as the efficiency of release and maturation of progeny viruses does not depend on the presence of
IDE
in the host cells, as it was shown by CRISPR/Cas9 edited
IDE
KO cells. However, HIV-1 mutants harboring
IDE
-insensitive p6 variants exhibit reduced virus replication capacity, a phenomenon that seems to depend on the presence of an X4-tropic Env. Furthermore, competing for
IDE
by exogenous insulin or inhibiting
IDE
by the highly specific inhibitor 6bK, also reduced virus replication. This effect could be specifically attributed to
IDE
since replication of HIV-1 variants coding for an
IDE
-insensitive p6 were inert towards
IDE
-inhibition. Our cumulative data support a model in which removal of p6 during viral entry is important for virus replication, at least in the case of X4 tropic HIV-1.
...
PMID:Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner. 2838 73
As part of the Pr55
Gag
polyprotein, p6 fulfills an essential role in the late steps of the replication cycle. However, almost nothing is known about the functions of the mature HIV-1 p6 protein. Recently, we showed that p6 is a bona fide substrate of the
insulin-degrading enzyme
(
IDE
), a ubiquitously expressed zinc metalloprotease. This phenomenon appears to be specific for HIV-1, since p6 homologs of HIV-2, SIV and EIAV were
IDE
-insensitive. Furthermore, abrogation of the
IDE
-mediated degradation of p6 reduces the replication capacity of HIV-1 in an Env-dependent manner. However, it remained unclear to which extent the
IDE
mediated degradation is phylogenetically conserved among HIV-1. Here, we describe two HIV-1 isolates with
IDE
resistant p6 proteins. Sequence comparison allowed deducing one single amino acid regulating
IDE
sensitivity of p6. Exchanging the N-terminal leucine residue of p6 derived from the
IDE
sensitive isolate HIV-1
NL4-3
with proline enhances its stability, while replacing Pro-1 of p6 from the
IDE
insensitive isolate SG3 with leucine restores susceptibility towards
IDE
. Phylogenetic analyses of this natural polymorphism revealed that the N-terminal leucine is characteristic for p6 derived from HIV-1 group M except for subtype A, which predominantly expresses p6 with an N-terminal proline. Consequently, p6 peptides derived from subtype A are not degraded by
IDE
. Thus,
IDE
mediated degradation of p6 is specific for HIV-1 group M isolates and not occasionally distributed among HIV-1.
...
PMID:The N-Terminus of the HIV-1 p6 Gag Protein Regulates Susceptibility to Degradation by IDE. 3054 91